Lung cancer diagnostics solutions

Lung cancer diagnostics solutions

Driving Personalized Healthcare with key ­markers for detection and subtyping

The statistics associated with lung cancer clearly demonstrate the aggressive nature of this deadly disease, Roche Tissue Diagnostics offers a robust menu of tools to aid in the diagnosis of patients facing this challenge. “With the introduction of targeted therapies that can result in dramatically different outcomes based on subtype, the importance of accurate classification has been amplified.”1

Our portfolio of products, which includes rabbit monoclonal antibodies, novel biomarkers and detection kits, delivers the high sensitivity and specificity needed from diagnostic assays. 

Our antibodies are ready-to-use on the ­fully-automated VENTANA BenchMark ­systems, which reduces the time to complete diagnosis and resources required with manual or semi-automated solutions.


Differentiating between adenocarcinoma and squamous cell carcinoma


Confidently differentiate between lung ­adenocarcinoma (ADC) and squamous cell carcinoma (SCC) with four key markers, including the p40 (BC28) Mouse Monoclonal Primary Antibody.

p40 (BC28) Mouse Monoclonal Primary Antibody
p40 (BC28) is a sensitive and specific antibody for the detection of the p40 (Np63) protein. In a panel with other key markers in our portfolio (TTF-1, CK 5/6, Napsin A), p40 (BC28) can provide an accurate and reliable method for differentiating pulmonary adenocarcinoma from squamous cell carcinoma.2


Squamous cell carcinoma stained positive with the p40 (BC28) assay using OptiView DAB IHC detection
Gain a clear view by detecting ALK and PD-L1 protein expression


NSCLC stained with VENTANA ALK (D5F3), and OptiView DAB IHC detection with AMP


VENTANA ALK (D5F3) Rabbit ­Monoclonal Primary Antibody
VENTANA ALK (D5F3) is indicated as an aid in identifying patients eligible for treatment with XALKORI (crizotinib). It is, therefore, critical that ALK positive patients are accurately identified. Shaw et al. highlights this importance and demonstrates that ALK testing via IHC represents a reliable and cost effective alternative to FISH.3 

Clone D5F3 has been identified as “one of the most promising antibodies for the detection of ALK rearrangement in NSCLC.” In a study of 296 patients with advanced NSCLC clinically referred for ALK testing, the “ultrasensitive” VENTANA ALK (D5F3) assay showed high correlation with FISH and 100 % sensitivity and specificity.4


NSCLC stained with VENTANA PD-L1 (SP263)


VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody
The VENTANA PD-L1 (SP263) antibody is produced against programmed death-ligand 1 (PD-L1) B7 homolog 1 (B7-H1, CD274). It recognizes a transmembrane bound glycoprotein that has a molecular mass of 45 – 55 kDa. This antibody produces membranous, and/or cytoplasmic staining.

It is indicated as an aid in the assessment of PD-L1 expression in non-small cell lung cancer (NSCLC) and other tumor types.5

1    Tacha, D., Yu, C., Bremer, R., Qi, W., Haas, T. (2012). Appl Immunohistochem Mol Morphol 20, 201-207.
2    Wei, Z., Hui, W., Yan, P., Bo, T., Lei, P., Da-Chuan, Z. (2014). Np63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens. Int J Clin Exp Pathol, 7(7), 4247-4253.
3    Shaw et al. (2011). J Natl. Compr. Canc. Netw. 9,1335-1341.
4    Minca et al. (2013). J Mol Diagn. 15(3).
5    Zou, W., Chen, L. (2008). Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol, 8(6), 467-77.